



## Spinal Cord Compression Caused by Metastasis of a Non-Seminomatous Testicular Tumour with a Predominant Yolk Sac Component in a 26-Year-Old Man

Di Gregorio M<sup>1\*</sup>, Pochet C<sup>2</sup>, Dupont M<sup>3</sup>, Nolleaux MC<sup>4</sup>, Lorge F<sup>1</sup> and D'Hondt L

<sup>1</sup>Department of Urology, CHU UCL, Namur (site-Godinne), Belgium

<sup>2</sup>Department of Surgery, CHU UCL, Namur (site-Godinne), Belgium

<sup>3</sup>Department of Radiology, CHU UCL, Namur (site Godinne), Belgium

<sup>4</sup>Department of Anatomopathology, CHU UCL, Namur (site Godinne), Belgium

<sup>5</sup>Department of Oncology, CHU UCL, Namur (site-Godinne), Belgium

### Abstract

**Background:** Pure testicular yolk sac tumours are extremely rare among adults, and there is no prior report of spinal cord compression syndrome due to yolk sac testis tumour metastasis in an adult.

**Case presentation:** Here we describe the case of a 26-year-old male with a testicular yolk sac tumour that was found when a vertebral metastasis caused spinal cord compression. Symptoms included lower back pain and a growing painless testicular mass. Treatment comprised emergency surgical spinal cord decompression and orchidectomy, followed by 3 cycles of bleomycin, etoposide, and platinum (BEP) chemotherapy, and then 3 cycles of etoposide and platinum and 40 Gy vertebral radiotherapy. One year later, cement leaked into the spinal duct, prompting a return of compression syndrome. Corporectomy was performed, followed by osteosynthesis. The patient's treatment was consolidated with 34 months and zoledronic acid administration. Although spinal metastasis from a yolk sac tumour is extremely rare, it must be considered in young adults with a testicular mass who exhibit pain or limb numbness. Such cases warrant rapid surgical decompression and radical orchidectomy, followed by adjuvant chemotherapy.

**Conclusion:** Our case is atypical due to the patient's age and the disease presentation. Spinal cord compression syndrome caused by yolk sac tumor metastasis is extremely rare in adulthood, and usually has a bad prognosis when diagnosed late.

**Keywords:** Yolk sac tumour; Spinal cord compression syndrome ; Adult; Cisplatin; Testicular tumour

**Abbreviations:** NSGCTs: Testicular Seminomas and Non-Seminomatous Germ Cell Tumours; CT: Computed Tomography; LDH: Lactate Dehydrogenase; beta-HCG: Gonadotropic Chorionic Hormone; MRI: Magnetic Resonance Imaging; <sup>18</sup>FDG-PET: 18-Fluorodeoxyglucose Positron Emission Tomography; PLAP: Phosphatase alkaline; MMO: Multidisciplinary Meeting of Oncology; BEP: Bleomycin, Etoposide, and Platinum; Gy: gray

### Introduction

Testicular cancer is rare among adults (representing 0.5% of all cancers), but accounts for 21% of all neoplasms in male adolescents and young adults (15-29 years of age) and is the most common solid cancer in this age group [1]. This cancer has two histological subtypes: testicular seminomas and non-seminomatous germ cell tumours (NSGCTs). The latter group includes embryonal carcinomas, teratomas, choriocarcinomas, and yolk sac tumours. Five-year survival rates vary based on histology, being over 95% for seminomas, and below 70% for NSGCTs (<50% for yolk sac tumours) [1].

A few cases have been reported in which a primary retroperitoneal tumour shows spinal column or spinal cord invasion, usually involving paediatric patients [2,3]. To our knowledge, the literature includes no previous report of an adult patient showing spinal cord compression syndrome due to metastasis of a NSGCT with a yolk sac component. Two reported cases have involved an extragonadal yolk sac tumour: one originating from the retroperitoneum [4], and the other from the mediastinum [5].

For NSGCTs in the paediatric population, recommended therapies

include an initial radical orchiectomy, followed by retroperitoneal lymph node dissection. In cases with recurrence or metastasis, cisplatin-based chemotherapy is administered, along with strengthening radiotherapy when necessary [6,7]. However, the treatment protocol is not well-defined [1]. In Europe, the current standard is metastasis-directed radiotherapy [7].

In the present case report, we describe an unusual presentation of a yolk sac testis tumour with spinal metastasis, and report the successful treatment administered in this case.

### Case Presentation

On December 30, 2005, a 26-year-old man with no remarkable medical history was admitted to the emergency room of our hospital for low back pain. His general practitioner had sent him to the hospital to undergo a computed tomography (CT) scan of the lumbo-sacral

**\*Corresponding author:** Marcelo Di Gregorio, CHU UCL Namur (site Godinne), 1 Av Gaston Thérèse, B-5530 Yvoir, Belgium, Tel: +32-81423478; Fax: +32-81423479; E-mail: [marcelo.digregorio@uclouvain.be](mailto:marcelo.digregorio@uclouvain.be)

**Received** March 27, 2020; **Accepted** April 17, 2020; **Published** April 24, 2020

**Citation:** Di Gregorio M, Pochet C, Dupont M, Nolleaux MC, Lorge F, et al. (2020) Spinal Cord Compression Caused by Metastasis of a Non-Seminomatous Testicular Tumour with a Predominant Yolk Sac Component in a 26-Year-Old Man. J Cancer Sci Ther 12: 06-09.

**Copyright:** © 2020 Di Gregorio M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


region. The patient had experienced major back pain for several months but had no neurological symptoms. He also had a painless scrotal mass that had been growing for 3 years, which had not been previously investigated. He had no fever and wasn't taking any medication. He was non-smoker, and his alcohol consumption was unremarkable.

Neurological examination was normal, but a positive Lasègue's sign was observed. Laboratory testing revealed an increased LDH of 1504 IU/L (normal range: 313-618 IU/L), increased alpha-foetoprotein of 80 957 ng/ml (normal range: <7 ng/ml), and normal beta-HCG of 22 mIU/L (normal range: <25 IU/ml).


The patient exhibited a 15-cm tumefaction in the right testis. This tumefaction was not erythematous, did not show ecchymosis, and was not painful or depressible upon palpation. It was not fixed to the skin, but rather to deeper tissues. Scrotal ultrasound revealed a right testicular mass exhibiting a heterogeneous echo structure with multiple small cystic components (Figure 1A). Contrast-enhanced multidetector computed tomography revealed an 8-mm right inferior pulmonary lobe nodule with a right testicular mass (Figure 1B), as well as spinal cord compression by a lesion of the 1<sup>st</sup> lumbar vertebra with epidural extension (Figure 2A). Magnetic resonance imaging of the full spinal cord revealed lumbar compression (Figure 2B), a neoplastic medullar replacement at the C4-C5 level, and a leptomeningeal increment in front of the brain stem. Cerebral MRI showed no other signs of leptomeningeal carcinomatosis.

To relieve the spinal cord compression, laminectomy was performed with vertebroplasty and fixation of the first lumbar vertebra. Right orchidectomy was also performed while the patient was under anaesthesia. The cervical lesion was considered stable and was not operated. A post-operative bone scan and 18-fluorodeoxyglucose positron emission tomography (<sup>18</sup>FDG-PET) revealed no additional lesions.

Pathological analysis revealed a malignant NSGCT comprising a major component of yolk sac tumour cells and a smaller component of anaplastic seminoma cells. At the centre of the tumour, these cells formed a structure called a Schiller-Duval corpus, which is a tapestry of loose tissue centred around a blood vessel with thin walls (Figure 3). The tunica vaginalis and albuginea were infiltrated, and there was substantial vascular permeation, but the epididymis and spermatic duct showed no invasion. Immunohistochemistry revealed diffuse alpha-foetoprotein expression among the tumour cells, with particularly high intensity seen in the yolk sac tumour cells. This cell population also exhibited cell membrane expression of the cytokeratins AE1/E3 and



**Figure 2:** (A) Axial contrast-enhanced multidetector computed tomography image at the level of the first lumbar vertebral body, showing vertebral fracture with peripheral soft tissue bulging. (B) Sagittal T2-weighted MRI of the spine showing pathological fracture of first lumbar vertebra with spinal cord compression.




**Figure 3:** Malignant germ cell tumour comprising a major component of yolk sac tumour cells and a smaller component of anaplastic seminoma cells. At the centre of the tumour is a structure called a Schiller-Duval corpus (arrow), in which the tumour cells form a tapestry of loose tissue centred around a blood vessel with thin walls (H&E staining, magnification x20).

CD<sub>117</sub> (c-kit). The minority tumour cells (anaplastic seminoma) were highly positive for PLAP and CD<sub>117</sub>. The tumour cells were negative for CD<sub>30</sub>, and beta-HCG was not contributive.

The final staging of the cancer was Stage IV pT<sub>4</sub> cN<sub>0</sub> pM<sub>1b</sub> S<sub>3</sub> yolk sac testicular neoplasia. After multidisciplinary meeting of oncology (MMO), the proposed treatment included 3 cycles (3 weeks each) of bleomycin, etoposide, and platinum (BEP) chemotherapy, followed by consolidation radiotherapy. Sperm cryopreservation was performed before starting BEP chemotherapy.

Twenty-four days after the patient's arrival in the emergency room, the first cycle of BEP chemotherapy was started. After 3 cycles, the decrease of alpha-foetoprotein to 16.4 ng/ml (normal range: <7 ng/ml) was so encouraging that we decided to continue treatment with cisplatin for three more cycles, but to stop treatment with bleomycin to spare the pulmonary function. After 4 cycles of EP chemotherapy (cisplatin and VP<sub>16</sub>) the alpha-foetoprotein level decreased to 4.2 ng/ml, which is within the normal range of <7 ng/ml.

One month after the end of the sixth cycle, bone scan imaging



**Figure 1:** (A) Ultrasound image of the right testicular mass, showing a heterogeneous echo structure with multiple small cystic components. (B) Axial contrast-enhanced multidetector computed tomography image showing a large heterogeneous testicular mass.

indicated disease expansion at the thoracic level, spreading to the 6<sup>th</sup> cost-vertebral articulation and articular epiphysis of L<sub>2</sub>. Thus, the patient was administered locoregional radiotherapy centred on L<sub>1</sub>, L<sub>2</sub>, and D<sub>6</sub>, with a total dose of 40 Gy over one month.

One year after the diagnosis, the primary neurologic symptoms recurred. This was found to be caused by an expulsion of the vertebroplasty cement into the spinal canal. We performed an L<sub>1</sub> corporectomy, followed by osteosynthesis from T<sub>11</sub> to L<sub>3</sub>. The removed fragments were sent for pathological analysis, which did not reveal any residual tumour cells. One year later, the patient started consolidation treatment with zoledronic acid (Zometa®) IV perfusion once every 4 weeks. The final administration of zoledronic acid was made 3.5 years after the surgery.

Following 3 cycles of BEP chemotherapy, 3 cycles of cisplatin + VP<sub>16</sub> chemotherapy, local radiotherapy, and 2 surgeries, the patient was in remission. Chemotherapy was well tolerated, and the patient showed a good response. Alpha-foetoprotein levels were completely normalized after only 4 cycles of platinum. The patient's Karnofsky performance scale index was maintained, and the spinal cord carcinomatosis on the cervical vertebrae remained stable. As of the most recent follow-up in September of 2018, 12 years after the initial diagnosis, the patient remains well and in complete remission.

## Discussion

Pure yolk sac tumours account for 70% of paediatric testicular germ cell tumours and are almost always found in infants and young children. On the other hand, pure yolk sac tumours are rare in adults [8], constituting only about 2.4% of testicular germ cell tumours and are identified as a component in 40% of mixed germ cell tumours [9]. The physiopathology of such tumours remains unclear. During the second half of the 20<sup>th</sup> century, an increasing incidence of testis tumours has been reported [10], but the reasons for this increase are unknown since the disease risk factors are poorly understood. Some research suggests that exposure to various factors in utero or during early childhood are likely important in determining an individual's risk level. Other findings indicate that testicular cancer development may be related to exposure to various factors in adolescence and adulthood, including occupational exposures in firefighting and aircraft maintenance, and environmental exposure to organochlorine pesticides [11]. Cryptorchidism is an established risk factor, associated with a relative risk of 2.23 if orchidopexy is performed before the age of 13 years and a relative risk of 5.54 if not [12]. However, in the vast majority of testicular cancer cases, the cause is unknown.

While prepubertal testicular teratomas rarely metastasize and have a good prognosis after orchidectomy alone, yolk sac tumours in adults are frequently malignant [13]. Thus, it seems that pure yolk sac tumours in adults behave differently from their juvenile counterparts and are comparable to other non-seminomatous germ cell tumours in the adult testis. Adult yolk sac tumours are also more likely to exhibit lymphatic spread, while juvenile tumours more commonly exhibit hematogenous spread, indicating that retroperitoneal lymph node dissection may be a reasonable treatment option in adult patients [14]. Our presently described patient did not present retroperitoneal lymphatic metastasis at the time of diagnosis. Therefore, the neurological metastasis was probably of hematogenic origin.

Historically, alpha-foetoprotein is the marker most widely used to diagnose yolk sac tumours. However, although alpha-foetoprotein immunoreactivity is found in the majority of tumours, it is often

variable and weak in intensity, and negative immunostaining for alpha-foetoprotein does not exclude the diagnosis [15]. A more recently described immunohistochemical marker is SALLA4, which is strongly positive in yolk sac tumours, including metastases, and appears to be a more sensitive marker than glypican-3 and alpha-foetoprotein [16].

The protocols for adjuvant therapy in paediatric cases of yolk sac tumours have changed over time to avoid overtreatment and to minimize drug toxicity to the patients [17]. Multidrug chemotherapy protocols using platinum-based regimens have improved survival to near 100% among prepubertal patients with yolk sac tumours [18,19]. Our present case is atypical due to the patient's age at onset. Yolk sac tumours usually affect paediatric patients [5,6]. Although our present patient was older than the paediatric patients treated in the literature [5], we decided to apply the standard yolk sac tumour treatment in our patient. The utilized chemotherapy regimen has also been used to treat other yolk sac tumours in the vertebral column, but those cases did not involve a primary testicular tumour [9,10]. Cisplatin-based treatment is reportedly an excellent adjuvant chemotherapy, that shows substantial benefits when treating stage II<sub>b</sub> (or higher) NSGCTs [3]. Our patient also received local radiotherapy. In the literature, it is recommended that treatment include a total dose of 30 Gy, administered in 10 fractions of 3 Gy each, because it has not been proven that 40 Gy produces better results in these kinds of metastases [18]. However, since the disease was discovered late in our present case, the radiotherapists deemed it appropriate to administer 40 Gy in total.

Another atypical aspect of our present case is that we identified a bone metastasis without finding any lymphatic node involvement upon <sup>18</sup>F-DG-PET. Thus, this case involved a high-grade cancer with no affected lymphatic nodes. Our patient was considered to have a poor prognosis based on the high alpha-foetoprotein level, and the presence of extrapulmonary metastases. Stage III NSGCTs reportedly have 5-year overall and disease-free survival rates of 44% and 29%, respectively [20]. However, our patient had stage IV cancer with a poor prognosis, and is still alive twelve years later. Moreover, our patient has a perfect normal life, with a Karnofsky performance scale index of 0. He has had no late side effects from the treatment and shows no signs of relapse.

## Conclusion

Spinal cord compression syndrome caused by yolk sac tumour metastasis is extremely rare in adulthood, and usually has a bad prognosis when diagnosed late. The patient in the present case was managed using spinal cord decompression, vertebral stabilization, orchiectomy, and early adjuvant radio chemotherapy, which produced good results in less than a year and a half, and over 12 years of disease-free survival. Alpha-foetoprotein showed great value in the monitoring of this patient and could be useful for detecting long-term relapse.

## Ethics Approval and Consent to Participate

Not applicable.

## Authors' Contributions

**Marcelo Di Gregorio:** Conceived, coordinated and designed of study. Took care of the patient in the emergency service and performed the surgery.

**Francis Lorge:** Helped to draft the manuscript and took care of the patient in the emergency service and performed the surgery.

**Corentin Pochet:** Helped to write the manuscript

**Michaël Dupont:** Radiologist (CHU UCL Namur site Godinne), performed the radiology examinations to discover the lesion.

**Marie Cécile Nollevaux:** Anatomopathologist (CHU UCL Namur site Godinne) performed pathological analysis revealed the malignant NSGCT.

**Lionel D'Hondt:** Oncologist (CHU UCL Namur site Godinne), has followed the patient to the oncology level and for his chemotherapy treatments. All authors read and approved the final manuscript

#### Acknowledgements

The authors acknowledge Axel Baily for picture edition and Edith Botek for reading support.

#### Consent for Publication

Written informed, consent was obtained from the patient for publications of this case reports and any accompanying images.

#### Availability of Data and Material

Data are available at the CHU UCL Namur.

#### Competing Interests

The authors declare that they have no competing interests.

#### Funding

No funding was obtained for this study.

#### References

1. Bleyer A, O'Leary M, Barr R, Ries LAG (2006) Male genital tract cancer: Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000. National Cancer institute, NIH Pub. N° 06-5767, Bethesda, MD.
2. Çolak A, Benli K, Berker M, Önel B (1991) Epidural metastasis of testicular yolk sac tumor: an unusual cause of spinal cord compression. *Pediatr Neurosurg* 17 : 139-141.
3. Lee JK, Kim SH, Kim JH, Kim IY, Kim TS, et al. (2002) Metastatic spinal cord compression of testicular yolk sac tumor. *Childs Nerv Syst* 18: 171-174.
4. Guzel A, Tatli M, Belen D, Secki H (2007) Spinal cord compression of primary extragonadal giant yolk sac tumor. *Spinal Cord* 45: 254.
5. Ajiboye RM, Nelson SD, Shamie AN (2015) Rare case of conus medullaris syndrome from a metastatic yolk sac tumor originating from the mediastinum of an adult male: A case report and review of the literature. *Int J Spine Surg* 9: 59.
6. Loblaw DA, Perry J, Chambers A, Laperriere NJ (2005) Systematic review of the diagnosis and management of malignant extradural spinal cord compression: The Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group. *J Clin Oncol* 23: 2028-2037.
7. Cole JS, Patchell RA (2008) Metastatic epidural spinal cord compression. *Lancet Neurol* 7: 459-466.
8. Jagtap SV (2012) Adult pure yolk sac tumor of the testis. *Online J Health Allied Scs* 11: 7-11.
9. Cao D, Humphrey PA (2011) Yolk sac tumor of the testis. *J Urol* 186: 1475-1476.
10. Sesterhenn IA, Davis CJ (2004) Pathology of germ cell tumors of the testis. *Cancer Control* 11: 374-387.
11. McGlynn, Katherine A, Trabert B (2012) Adolescent and adult risk factors for testicular cancer. *Nat Rev Urol* 9: 339-349.
12. Bakaris SRS, Tunali N (2004) Testicular mixed germ cell tumor with polyembryoma component in brothers. *Pediatr Dev Pathol* 8: 92-97.
13. Taskinen S, Fagerholm R, Aronniemi J, Rintala R, Taskinen M (2008) Testicular tumors in children and adolescents. *J Pediatric Urol* 4: 134-137.
14. Foster RS, Hermans B, Bihrlie R, Donohue JP (2000) Clinical stage I pure yolk sac tumor of the testis in adults has different clinical behavior than juvenile yolk sac tumor. *J Urol* 164: 1943-1944.
15. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, et al. (2011) EAU guidelines on testicular cancer: update. *European Urol* 60: 304-319.
16. Cao D, Humphrey PA, Allan RW (2009) SALL4 is a novel sensitive and specific marker for metastatic germ cell tumors, with particular utility in detection of metastatic yolk sac tumors. *Cancer* 115: 2640-2651.
17. Mann JR, Raafat F, Robinson K, Imeson J, Gornall P, et al. (2000) The United Kingdom Children's Cancer Study Group's second germ cell tumor study: Carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. *J Clin Oncol* 18: 3809-3818.
18. Greenberg HS, Kim JH, Posner JB (1980) Epidural spinal cord compression from metastatic tumor: Results with a new treatment protocol. *Ann Neurol* 8: 361.
19. Motzer RJ, Sheinfeld J, Mazumdar M, Bajorin DF, Bosl GJ, et al. (1995) Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors. *J Clin Oncol* 13: 2700-2704.
20. Ataergin S, Ozet A, Arpacı F, Kilic S, Beyzadeoglu M, et al. (2007) Outcome of patients with stage II and III non seminomatous germ cell tumors: Results of a single center. *Indian J Cancer* 44: 6-11.